What is the ARS Pharmaceuticals securities class action lawsuit about?

The ARS Pharmaceuticals securities class action alleges that the company made false and misleading statements to investors while concealing material adverse facts about the expected timeline for expanded insurance coverage for its neffy product through CVS Caremark. As a result of these allegedly misleading statements, investors are said to have purchased ARS Pharmaceuticals (NASDAQ: SPRY) securities at artificially inflated prices.

Who is eligible to join the ARS Pharmaceuticals SPRY class action lawsuit?

Investors who purchased ARS Pharmaceuticals securities between March 9, 2026 and June 24, 2026 may be eligible to participate in the class action. If you purchased SPRY shares during this class period and suffered losses, you may have legal rights worth exploring.

What is the deadline to file a lead plaintiff motion in the ARS Pharmaceuticals lawsuit?

The deadline to seek appointment as lead plaintiff in the ARS Pharmaceuticals securities class action is October 5, 2026. Missing this deadline does not necessarily prevent you from recovering damages as a class member, but you must act by this date if you wish to lead the case.

What did ARS Pharmaceuticals allegedly misrepresent to investors?

The lawsuit alleges that ARS Pharmaceuticals defendants made overwhelmingly positive public statements to investors while simultaneously concealing material adverse facts about the expected timeline for neffy's expanded insurance coverage through CVS Caremark. These statements allegedly caused investors to purchase SPRY securities at prices that were artificially inflated.

What is neffy and what role does it play in the ARS Pharmaceuticals lawsuit?

Neffy is an ARS Pharmaceuticals product at the center of the securities fraud allegations. The complaint alleges that defendants misled investors about the expected timeline for expanded insurance coverage of neffy through CVS Caremark, which is alleged to have been a material fact that was concealed from the market.

In which court was the ARS Pharmaceuticals securities class action filed?

The ARS Pharmaceuticals securities class action was filed in the United States District Court for the Southern District of California. Investors seeking more information about the case or their rights can consult with securities counsel familiar with this jurisdiction.

What should I do if I lost money on ARS Pharmaceuticals stock during the class period?

If you purchased ARS Pharmaceuticals (NASDAQ: SPRY) shares between March 9, 2026 and June 24, 2026 and suffered losses, you may have the right to participate in the class action recovery or seek appointment as lead plaintiff before the October 5, 2026 deadline. Consulting with a securities attorney can help you understand your options and what documentation, such as trading records, you may need.

ARS Pharmaceuticals Inc. - Faruqi & Faruqi LLP

ARS Pharmaceuticals Inc.

Join Action

Case Details

Ticker SPRY

Class Period 03/09/2026 - 06/24/2026

Lead Plaintiff Deadline 10/05/2026

Days Left to Seek Lead Plaintiff

If you are an ARS Pharmaceuticals Inc. investor who suffered a loss and would like to learn more, you can provide your information below:

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In ARS Pharmaceuticals To Contact Him Directly To Discuss Their Options

If you purchased or acquired securities in ARS Pharmaceuticals between March 9, 2026 and June 24, 2026 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).

Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against ARS Pharmaceuticals Inc. (“ARS Pharmaceuticals” or the “Company”) (NASDAQ: SPRY) and reminds investors of the October 05, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.

As detailed below, the complaint alleges that the Company and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose that: Defendants provided overwhelmingly positive statements to investors while, at the same time, disseminating false and misleading statements and/or concealing material adverse facts concerning the expected timeline for the expanded insurance coverage for neffy through CVS Caremark. This caused Plaintiff and other shareholders to purchase ARS’s securities at artificially inflated prices.

Lead Plaintiff Deadline: October 05, 2026

Call Partner Josh Wilson at 877-247-4292 or 212-983-9330 (Ext. 1310). Or submit your information below to learn about your rights.

Join Action

ARS Pharmaceuticals Inc.

Monetary Losses ($) *

Website URL

First Name *

Last Name *

Telephone *

Email *

Street Address

City

State

Zip Code

Purchases

1	Purchases Options Price per Share Date # of Shares Principal Amount Amount Paid Series or Cusip # of Contracts Price per Contract Exercise Price Expiration Date
1	Purchases Options Price per Share Date # of Shares Principal Amount Amount Paid Series or Cusip # of Contracts Price per Contract Exercise Price Expiration Date

Add Row

Sales

1	Sales Options Price per Share Date # of Shares Principal Amount Amount Paid Series or Cusip # of Contracts Price per Contract Exercise Price Expiration Date
1	Sales Options Price per Share Date # of Shares Principal Amount Amount Paid Series or Cusip # of Contracts Price per Contract Exercise Price Expiration Date

Add Row

Upload your trades here:

Accepted file types: xls, xlsx, doc, docx, pdf, jpg, jpeg, png, Max. file size: 50 MB, Max. files: 5.
You may redact account numbers from your uploaded documents.

File name:

File size:

Select File

Does not establish an attorney-client relationship *

By clicking this box, I acknowledge that this form is not intended to and does not establish an attorney-client relationship between myself and Faruqi & Faruqi LLP, and that the submission or receipt of information via this form, e-mail or telephone does not create an attorney-client relationship.

Case

Users to notify